Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Katy Newton

Katy Newton

VP Process Development, Achilles Therapeutics
Katy serves as VP Process Development at Achilles and has worked in the cell therapy field for over 10 years. She has extensive experience in developing adoptive cell therapy products and managing GMP production. Prior to joining Achilles, she was VP of Process Development at Cell Medica Ltd. where she led the process development and optimisation that enabled the transfer of their first oncology cell product from an academic partner to an external contract manufacturer and subsequent IND filing. Katy holds a PhD in T cell immunology from University College London (ICH) and a BSc in Biochemistry with applied molecular biology from University of Manchester (UMIST).
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd